TG Therapeutics (TGTX) Misses Q1 EPS by 13c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- US stocks set for higher open as AI trade steadies; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 6% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mail
Get Alerts TGTX Hot Sheet
Join SI Premium – FREE
TG Therapeutics (NASDAQ: TGTX) reported Q1 EPS of $0.03, $0.13 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $119.7 million versus the consensus estimate of $117.13 million.
GUIDANCE:
TG Therapeutics sees FY2025 revenue of $575 million, versus the consensus of $553 million.
For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic PBC: adjusted operating income increased for the three months ended September 30, 2026 to $2.5 billion
- EMCOR Group (EME) PT Lowered to $920 at Cantor Fitzgerald
- Melius on Marriott (MAR): 'There wasn't much to complain about this quarter'
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
